Evidence map›Paper›PMID 38899638›Full record

ArticleUrology practice2024

Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Mixed Methods Approach to Identify Effective Interventions.

Daniel D Joyce, Kasey R Boehmer, Celia C Kamath, Christina M LaVecchia, Vidit Sharma, Phillip J Schulte, Jon C Tilburt, David F Penson, Stephen A Boorjian

Abstract read
In one paragraph

Article in Urology practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Navigating work after prostate cancer treatment: a systematic review of qualitative research.Journal of cancer survivorship : research and practice · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Daniel D JoyceDepartment of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Kasey R BoehmerKnowledge and Evaluation Research (KER) Unit, Mayo Clinic, Rochester, Minnesota.
Celia C KamathDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Christina M LaVecchiaKnowledge and Evaluation Research (KER) Unit, Mayo Clinic, Rochester, Minnesota.
Vidit SharmaDepartment of Urology, Mayo Clinic, Rochester, Minnesota.
Phillip J SchulteDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Jon C TilburtDepartment of General Internal Medicine, Mayo Clinic, Scottsdale, Arizona.
David F PensonDepartment of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Stephen A BoorjianDepartment of Urology, Mayo Clinic, Rochester, Minnesota.

Funding

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
NCATS NIH HHS UL1 TR002377
6 · The paper itself

Abstract

introductionFinancial toxicity associated with treatments for metastatic prostate cancer remains poorly defined. We sought to understand aspects of financial toxicity not captured in a commonly employed financial toxicity questionnaire and identify potential interventions to help alleviate financial toxicity through a convergent mixed methods approach.

methodsPatients seen at our institution's advanced prostate cancer clinic were approached for completion of the Comprehensive Score for Financial Toxicity (COST-FACIT) questionnaire (quantitative analysis). A maximal variation purposive sample was chosen to participate in focus group discussions (qualitative analysis). Conventional content analysis was performed using an inductive approach. COST-FACIT scores were compared between patients experiencing high and low financial toxicity using Wilcoxon rank sum test.

resultsThree themes were identified through qualitative analysis: (1) workload, (2) coping strategies, and (3) communication. We found alignment with the existing theory of financial capacity across our findings. Two unique aspects of financial toxicity emerged that were not assessed quantitatively and deemed to be significant. Specifically, cost transparency (including health care teams knowledgeable about and willing to discuss costs) and inclusion of informal caregivers in financial toxicity screening and decision-making may guide future interventions aimed at limiting financial toxicity in this population.

conclusionsProlonged treatment courses involving multiple lines of treatment with varying costs result in distinct financial toxicity components for patients with metastatic prostate cancer that are not assessed with COST-FACIT. Improving cost transparency, health care team knowledge and engagement, and providing resources to support informal caregivers may have a significant impact on the financial toxicity experienced by these patients.

Indexed as

Prostatic NeoplasmsAdaptation, PsychologicalAgedCost of IllnessFocus GroupsHumansMaleMiddle AgedNeoplasm MetastasisSurveys and QuestionnairesWorkloadadaptationcost of illnessfinancial stressprostatic neoplasmsquality of life

Identifiers

PMID38899638
PMCPMC11192241

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.